Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, discusses viable options for combining venetoclax with targeted therapies in acute myeloid leukemia (AML). Specifically outlined is venetoclax combined with ivosidenib, an IDH1 inhibitor, as well as with gilteritinib, a FLT3 inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).